Incyte – Talk Bio

Incyte’s Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection

3 weeks ago talkbio0Tagged Approved, Clinical Trials, Combination Drug Therapy, first-line therapy, Immunotherapy, Incyte, Inhibitor, Malignant neoplasm of anus, PDCD1 gene, POD1UM-303, Retifanlimab, United States Food and Drug Administration, Zynyz

Incyte; Zynyz; retifanlimab; FDA approval; anal cancer; PD-1 inhibitor; first-line therapy; immunotherapy; clinical trial; POD1UM-303; combination chemotherapy

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

4 months ago talkbio0Tagged Aortic Valve Insufficiency, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Cancer Pipelines Contract: Incyte and iTeos Discontinue Drug Candidates Amid Underwhelming Clinical Results

6 months ago talkbio0Tagged Cancer Pipelines, Clinical Trials, drug candidates, Incyte, iTeos, oncology research

Incyte, iTeos, cancer pipelines, drug candidates, clinical trials, disappointing data, pipeline cuts, oncology research.

Incyte Unveils Promising Monjuvi Data at ASH24, Paving Way for FDA Label Expansion in Follicular Lymphoma

6 months ago talkbio0Tagged ASH24, expansion, Incyte, Lymphoma, Follicular, Monjuvi, Phase 3 trial, United States Food and Drug Administration

Incyte, Monjuvi, ASH24, Follicular Lymphoma, Label Expansion, FDA, Phase 3 Trial

Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced

7 months ago talkbio0Tagged asset, cull, Drug Industry, Incyte, News [Publication Type]

Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry

Incyte’s PD-1 Drug Zynyz: A Strategic Pipeline Component Despite Recent Trial Success

9 months ago talkbio0Tagged Approved, Clinical Trials, Incyte, Inhibitor, Malignant neoplasm of anus, PDCD1 gene, United States Food and Drug Administration, Zynyz

Incyte, Zynyz, PD-1 inhibitor, anal cancer, pipeline strategy, clinical trials, FDA approval

Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma

10 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, expansion, Incyte, Labels (device), Lymphoma, Follicular, Monjuvi, MorphoSys, Phase 3 Clinical Trials, tafasitamab, United States Food and Drug Administration

Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.

Incyte and Syndax Secure FDA Approval for Niktimvo, a Breakthrough Treatment for Chronic Graft-Versus-Host Disease

10 months ago talkbio0Tagged allogeneic stem cell transplant, Approved, axatilimab-csfr, Chronic graft-versus-host disease, Graft-vs-Host Disease, Incyte, Niktimvo, Syndax, United States Food and Drug Administration

Incyte, Syndax, Niktimvo, FDA approval, graft-versus-host disease, GVHD, axatilimab-csfr, chronic GVHD, allogeneic stem cell transplant

Incyte Discontinues Five Early-Stage Oncology Programs in Pipeline Refocus

10 months ago talkbio0Tagged cancer pipeline, Community Clinical Oncology Program, Incyte, inhibitors, PD-L1, R&D, strategic review

Incyte, cancer pipeline, oncology programs, PD-L1 inhibitors, strategic review, R&D refocus

Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials

10 months ago talkbio0Tagged Carcinoma of anal margin, Incyte, Inhibitor, Non-Small Cell Lung Carcinoma, PDCD1 gene, Phase 3, Zynyz

Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer